Maxim Group analyst Naz Rahman maintained a Buy rating on Cingulate Inc (CING – Research Report) yesterday and set a price target of $3.00. The company’s shares closed yesterday at $1.56.
Rahman covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Neurosense Therapeutics Ltd., and Processa Pharmaceuticals. According to TipRanks, Rahman has an average return of -10.6% and a 32.67% success rate on recommended stocks.
Currently, the analyst consensus on Cingulate Inc is a Moderate Buy with an average price target of $4.25.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.20 and a one-year low of $0.66. Currently, Cingulate Inc has an average volume of 708.6K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CING in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Read More on CING:
- Cingulate Pops after Positive Topline Data
- Cingulate announces top-line results from CTx-1301-003 study
- Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
- Cingulate initiated with a Buy at H.C. Wainwright
- Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
